SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Pictured: Roche Diagnostics building in California
Gene therapy
Roche Inks Potential $1B Gene Therapy Deal With Dyno, Eyes Neurological Diseases
With an upfront payment of $50 million from Roche, the partnership will leverage Dyno Therapeutics’ in vivo gene therapy delivery technology, which synthesizes virus capsids with better functionality and manufacturability.
October 24, 2024
 · 
2 min read
 · 
Tristan Manalac
Business
Steady But Slow: Future Outlook For Investment
In this episode of Denatured, Lori and guests from Teva Pharmaceuticals and TOWER Capital review the investment landscape this year and the policies influencing investment heading into 2025.
October 24, 2024
 · 
1 min read
 · 
Lori Ellis
Novo Nordisk advertising flags and logo on facade
Editorial
Why It’s OK to Talk About Catalent’s Pending Buyout by ‘Novo’
The group of like-named companies that include Novo Holdings and Novo Nordisk—the two tied to a multibillion-dollar buyout of Catalent currently under FTC review—ultimately send proceeds to the Novo Nordisk Foundation, one of the world’s largest charitable foundations.
October 24, 2024
 · 
6 min read
 · 
Jef Akst
3D illustration of tow GLP-1 therapy autoinjectors
Diabetes
GLP-1 Prescriptions for Type 1 Diabetes Spike Despite Lack of FDA Approval: Study
While the regulator has not approved their use in type 1 diabetes, off-label prescribing for GLP-1 receptor agonists has sharply increased, according to researchers, who warn about the risk of serious side effects such as ketoacidosis.
October 24, 2024
 · 
2 min read
 · 
Tristan Manalac
GLP-1 injector pens and pills against colorful background
Weight loss
Viking to Accelerate Development of Obesity Drug With Two Q4 Catalysts
Following an end-of-Phase II meeting with the FDA in the fourth quarter, Viking Therapeutics plans to push its subcutaneous obesity therapy VK2735 into late-stage development and to start a Phase II trial for an oral formulation.
October 24, 2024
 · 
2 min read
 · 
Tristan Manalac
CDC approved vaccines for adults to boost the immu
Vaccines
CDC Panel Recommends Merck and Pfizer Pneumococcal Vaccines for Adults Aged 50–64
The CDC’s Advisory Committee on Immunization Practices on Wednesday backed the use of Merck’s Capvaxive and Pfizer’s Prevnar 20 in adults between 50-64 years of age, opening a bigger market for the respective companies.
October 24, 2024
 · 
2 min read
 · 
Tristan Manalac
Boston harbor and financial district
Job Creations
Massachusetts Tax Incentives for Moderna, Vertex and More Creating 1,155 Jobs
Nineteen companies are receiving $21.4 million total in tax incentive awards to create 1,155 new life sciences jobs in Massachusetts. Moderna and Vertex received the largest awards and will add over 600 combined jobs.
October 24, 2024
 · 
4 min read
 · 
Angela Gabriel
IN PARTNERSHIP WITH PATSNAP
Webinar: Revolutionizing Biologics Discovery: Harnessing the Power of AI and Patent Data
This webinar explores the pivotal role of patent data in overcoming the data challenges faced by generative AI models in drug discovery, particularly for biologics. Watch now.
October 23, 2024
 · 
1 min read
 · 
BioSpace Insights
PBMs
Deep Dive: Biopharma in the 2024 Presidential Election
On election day, Tuesday, November 5, Americans will choose between former President Donald Trump and current Vice President Kamala Harris for their next president. The election will also see the rearrangement of Congress.
October 23, 2024
 · 
2 min read
 · 
Annalee Armstrong
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS